Jeremy Cobbold

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Peter Eddowes, M. Sasso, Michael Allison et al. · Gastroenterology · 2019 · 1.3K citations · Full text

Hepatology, Liver Stiffness Measurement, Nonalcoholic Fatty Liver Disease +10

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Philip N. Newsome, M. Sasso, Jonathan J Deeks et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 729 citations · Full text

Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity

Michael Pavlides, Rajarshi Banerjee, Elizabeth M. Tunnicliffe et al. · Liver International · 2016 · 189 citations · Full text

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

Yasaman Vali, Jenny Lee, Jérôme Boursier et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 171 citations · Full text

Metabolic Syndrome, Biomarker (Medicine), Metabolic Associated Steatohepatitis +14